Anand Sharma to Paclitaxel
This is a "connection" page, showing publications Anand Sharma has written about Paclitaxel.
Connection Strength
0.227
-
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
Score: 0.090
-
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Score: 0.087
-
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 02; 23(2):259-269.
Score: 0.050